Table of Contents
WASHINGTON — The Pharmaceutical Care Management Association (PCMA) released the following statement on a Medicare Part D report released by the Office of Inspector (OIG), U.S. Department of Health and Human Services (HHS):
Mark Merritt
“This report finally debunks the myth that drugmakers have somehow been compelled to raise prices because of the discounts and rebates health plans and PBMs demand to reduce overall costs,” said PCMA president and chief executive officer Mark Merritt.
Key findings from the report include:
- Part D unit costs for brand-name drugs rose nearly 6 times faster than inflation from 2011 to 2015.
- Despite the substantial growth in rebates, the gap between total reimbursement and total rebates increased from 2011 to 2015.
- The percentage of brand-name drugs for which manufacturers paid rebates decreased.
- The number of brand-name drugs with rebates dropped from 72%t to 61%.
- Increases in Part D unit costs for brand-name drugs led to greater overall Medicare Part D spending and higher beneficiary out-of-pocket costs for these drugs.
- For nearly half of brand-name drugs reimbursed by Part D from 2011 to 2015, unit costs increased at least 50%.
- The total number of prescriptions for brand-name drugs decreased 17%.
- Brand-name drugs with utilization decreases had greater increases in average unit costs.
